← FDA DRUG APPROVALS

FDA ANDA · ANDA063098

ERYTHROMYCIN

Sponsor: BARR

APPLICATION
ANDA063098
TYPE
ANDA
ORIGINAL APPROVAL
1989-05-04
LATEST ACTION
2001-09-27
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Discontinued

Products

ERYTHROMYCINDiscontinued
ERYTHROMYCIN 250MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2001-09-27Labeling · Supplement 13AP
2001-05-21Labeling · Supplement 12AP
1999-12-21Manufacturing (CMC) · Supplement 11AP
1999-05-20Manufacturing (CMC) · Supplement 10AP
1998-12-01Manufacturing (CMC) · Supplement 9AP
1998-11-02Manufacturing (CMC) · Supplement 8AP
1995-05-08Manufacturing (CMC) · Supplement 5AP
1994-12-23Manufacturing (CMC) · Supplement 7AP
1994-10-11Manufacturing (CMC) · Supplement 6AP
1993-08-11Labeling · Supplement 4AP
1992-04-03Manufacturing (CMC) · Supplement 3AP
1992-04-03Manufacturing (CMC) · Supplement 1AP
1989-05-04OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →